{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:53:04Z","timestamp":1783007584313,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03597-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:51:07Z","timestamp":1752137467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Roles of JAK-STAT signaling and granulocyte\u2013macrophage colony-stimulating factor in the development of osteitis and bone microstructure changes in rheumatoid arthritis"],"prefix":"10.1186","volume":"27","author":[{"given":"Tsuneyasu","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Katsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirei","family":"Shirakashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"3597_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid Arthritis - Common origins, divergent mechanisms. N Engl J Med. 2023;388:529\u201342.","journal-title":"N Engl J Med"},{"key":"3597_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/ard.61.11.1007","volume":"61","author":"BJ Harrison","year":"2002","unstructured":"Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2002;61:1007\u201311.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/ard.2007.086348","volume":"68","author":"M G\u00fcler-Y\u00fcksel","year":"2009","unstructured":"G\u00fcler-Y\u00fcksel M, Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Groenendael JHLM, Mall\u00e9e C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2007.073817","volume":"67","author":"M G\u00fcler-Y\u00fcksel","year":"2008","unstructured":"G\u00fcler-Y\u00fcksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Hulsmans HMJ, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67:823\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/ard.2008.088245","volume":"68","author":"ML Hetland","year":"2009","unstructured":"Hetland ML, Ejbjerg B, H\u00f8rslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384\u201390.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1136\/annrheumdis-2014-205208","volume":"73","author":"A Krabben","year":"2014","unstructured":"Krabben A, Stomp W, van Nies Ja, Huizinga B, van der Heijde TWJ, Bloem D. MRI-detected subclinical joint inflammation is associated with radiographic progression. Ann Rheum Dis. 2014;73:2034\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/art.41229","volume":"74","author":"D Simon","year":"2022","unstructured":"Simon D, Kleyer A, Cong DB, Hueber A, Bang H, Ramming A, et al. Microstructural bone changes are associated with Broad-Spectrum autoimmunity and predict the onset of rheumatoid arthritis. Arthritis Rheumatol. 2022;74:418\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"3597_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854\u201360.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR9","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1136\/annrheumdis-2015-208138","volume":"75","author":"HW van Steenbergen","year":"2016","unstructured":"van Steenbergen HW, Mangnus L, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75:1824\u201330.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/annrheumdis-2017-211649","volume":"77","author":"B Smiljanovic","year":"2018","unstructured":"Smiljanovic B, Radzikowska A, Kuca-Warnawin E, Kurowska W, Gr\u00fcn JR, Stuhlm\u00fcller B, et al. Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint. Ann Rheum Dis. 2018;77:300\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR11","first-page":"465","volume":"24","author":"T Tomita","year":"1997","unstructured":"Tomita T, Shimaoka Y, Kashiwagi N, Hashimoto H, Kawamura S, Lee SB, et al. Enhanced expression of CD14 antigen on myeloid lineage cells derived from the bone marrow of patients with severe rheumatoid arthritis. J Rheumatol. 1997;24:465\u20139.","journal-title":"J Rheumatol"},{"key":"3597_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/ard.2007.071977","volume":"67","author":"EA Haavardsholm","year":"2008","unstructured":"Haavardsholm EA, B\u00f8yesen P, \u00d8stergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008;67:794\u2013800.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/art.11162","volume":"48","author":"FM McQueen","year":"2003","unstructured":"McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:1814\u201327.","journal-title":"Arthritis Rheum"},{"key":"3597_CR14","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.42617","volume":"75","author":"D Simon","year":"2023","unstructured":"Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY, et al. Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional BARE BONE trial. Arthritis Rheumatol. 2023;75:1923\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"3597_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.171469","volume":"46","author":"C Peterfy","year":"2019","unstructured":"Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, et al. MRI and dose selection in a phase II trial of baricitinib with conventional synthetic Disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 2019;46:887\u201395.","journal-title":"J Rheumatol"},{"key":"3597_CR16","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","volume":"12","author":"S Adam","year":"2020","unstructured":"Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M\u00fcller DIH, et al. JAK Inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med. 2020;12:eaay4447.","journal-title":"Sci Transl Med"},{"key":"3597_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41467-019-13853-4","volume":"11","author":"D Regan-Komito","year":"2020","unstructured":"Regan-Komito D, Swann JW, Demetriou P, Cohen ES, Horwood NJ, Sansom SN, et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat Commun. 2020;11:155.","journal-title":"Nat Commun"},{"key":"3597_CR18","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1172\/JCI60920","volume":"122","author":"JF Charles","year":"2012","unstructured":"Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest. 2012;122:4592\u2013605.","journal-title":"J Clin Invest"},{"issue":"2","key":"3597_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bone.2006.09.003","volume":"40","author":"R Lari","year":"2007","unstructured":"Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, et al. Macrophage lineage phenotypes and osteoclastogenesis\u2013complexity in the control by GM-CSF and TGF-beta. Bone. 2007;40(2):323\u201336.","journal-title":"Bone"},{"key":"3597_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1359\/JBMR.0301232","volume":"19","author":"JM Hodge","year":"2004","unstructured":"Hodge JM, Kirkland MA, Aitken CJ, Waugh CM, Myers DE, Lopez CM, et al. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Min Res. 2004;19:190\u20139.","journal-title":"J Bone Min Res"},{"key":"3597_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood.V74.4.1295.1295","volume":"74","author":"N Kurihara","year":"1989","unstructured":"Kurihara N, Suda T, Miura Y, Nakauchi H, Kodama H, Hiura K, et al. Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood. 1989;74:1295\u2013302.","journal-title":"Blood"},{"key":"3597_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/jbmr.5650060912","volume":"6","author":"N Takahashi","year":"1991","unstructured":"Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M, Suda T. Role of colony-stimulating factors in osteoclast development. J Bone Min Res. 1991;6:977\u201385.","journal-title":"J Bone Min Res"},{"key":"3597_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1172\/JCI1333","volume":"101","author":"NJ Horwood","year":"1998","unstructured":"Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 1998;101:595\u2013603.","journal-title":"J Clin Invest"},{"key":"3597_CR24","doi-asserted-by":"publisher","first-page":"16163","DOI":"10.1074\/jbc.M412713200","volume":"280","author":"MS Kim","year":"2005","unstructured":"Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280:16163\u20139.","journal-title":"J Biol Chem"},{"key":"3597_CR25","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","volume":"54","author":"K Ishigaki","year":"2022","unstructured":"Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet. 2022;54:1640\u201351.","journal-title":"Nat Genet"},{"key":"3597_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41588-022-01087-y","volume":"54","author":"S Gazal","year":"2022","unstructured":"Gazal S, Weissbrod O, Hormozdiari F, Dey KK, Nasser J, Jagadeesh KA, et al. Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nat Genet. 2022;54:827\u201336.","journal-title":"Nat Genet"},{"key":"3597_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41588-018-0047-6","volume":"50","author":"M Kanai","year":"2018","unstructured":"Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. Nat Genet. 2018;50:390\u2013400.","journal-title":"Nat Genet"},{"key":"3597_CR28","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1186\/ar3364","volume":"13","author":"HM Lee","year":"2011","unstructured":"Lee HM, Sugino H, Aoki C, Shimaoka Y, Suzuki R, Ochi K, et al. Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis. Arthritis Res Ther. 2011;13:R89.","journal-title":"Arthritis Res Ther"},{"key":"3597_CR29","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2009","unstructured":"Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the pathway interaction database. Nucleic Acids Res. 2009;37:D674\u2013679.","journal-title":"Nucleic Acids Res"},{"key":"3597_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18:415\u201329.","journal-title":"Nat Rev Rheumatol"},{"key":"3597_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/ar4035","volume":"14","author":"FM McQueen","year":"2012","unstructured":"McQueen FM. Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther. 2012;14:224.","journal-title":"Arthritis Res Ther"},{"key":"3597_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/art.22496","volume":"56","author":"E Jimenez-Boj","year":"2007","unstructured":"Jimenez-Boj E, N\u00f6bauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus AH, Kainberger F, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum. 2007;56:1118\u201324.","journal-title":"Arthritis Rheum"},{"key":"3597_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/ard.2008.096024","volume":"68","author":"N Dalbeth","year":"2009","unstructured":"Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis. 2009;68:279\u201382.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR34","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1182\/blood-2009-04-215020","volume":"114","author":"M Hiasa","year":"2009","unstructured":"Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood. 2009;114:4517\u201326.","journal-title":"Blood"},{"key":"3597_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","volume":"45","author":"B Becher","year":"2016","unstructured":"Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. 2016;45:963\u201373.","journal-title":"Immunity"},{"key":"3597_CR36","doi-asserted-by":"publisher","first-page":"101518","DOI":"10.1016\/j.smim.2021.101518","volume":"54","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, De Feo D, Becher B. GM-CSF: master regulator of the T cell-phagocyte interface during inflammation. Semin Immunol. 2021;54:101518.","journal-title":"Semin Immunol"},{"key":"3597_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/ar3379","volume":"28","author":"B Zhao","year":"2011","unstructured":"Zhao B, Ivashkiv LB. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Therapy. 2011;28:13:234.","journal-title":"Arthritis Res Therapy"},{"key":"3597_CR38","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1172\/JCI93356","volume":"127","author":"G Mbalaviele","year":"2017","unstructured":"Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. J Clin Invest. 2017;127:2030\u20139.","journal-title":"J Clin Invest"},{"key":"3597_CR39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/annrheumdis-2014-206359","volume":"74","author":"M \u00d8stergaard","year":"2015","unstructured":"\u00d8stergaard M, Jacobsson LTH, Schaufelberger C, Hansen MS, Bijlsma JWJ, Dudek A, et al. MRI assessment of early response to certolizumab Pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis. 2015;74:1156\u201363.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/annrheumdis-2013-204762","volume":"73","author":"PG Conaghan","year":"2014","unstructured":"Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, et al. The effects of Tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014;73:810\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1471-4906(02)02260-3","volume":"23","author":"JA Hamilton","year":"2002","unstructured":"Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002;23:403\u20138.","journal-title":"Trends Immunol"},{"key":"3597_CR42","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood.V75.12.2292.2292","volume":"75","author":"C Caux","year":"1990","unstructured":"Caux C, Saeland S, Favre C, Duvert V, Mannoni P, Banchereau J. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34\u2009+\u2009hematopoietic progenitor cells. Blood. 1990;75:2292\u20138.","journal-title":"Blood"},{"key":"3597_CR43","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1136\/ard-2023-224449","volume":"82","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, et al. Anti-GM-CSF Otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023;82:1527\u201337.","journal-title":"Ann Rheum Dis"},{"key":"3597_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41232-023-00293-3","volume":"43","author":"M Komagamine","year":"2023","unstructured":"Komagamine M, Komatsu N, Ling R, Okamoto K, Tianshu S, Matsuda K, et al. Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss. Inflamm Regen. 2023;43:44.","journal-title":"Inflamm Regen"},{"key":"3597_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fimmu.2019.00884","volume":"10","author":"F Wang","year":"2019","unstructured":"Wang F, Luo A, Xuan W, Qi L, Wu Q, Gan K, et al. The bone marrow edema links to an osteoclastic environment and precedes synovitis during the development of collagen induced arthritis. Front Immunol. 2019;10:884.","journal-title":"Front Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03597-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:20:26Z","timestamp":1757218826000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03597-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3597"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03597-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Kyoto University Animal Ethics Committee (approval number Medkyo 16106\u201323104). All experiments using human samples were approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (approval number R1166-3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TY has received speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., and Eli Lilly Japan K.K. MH has received research grants from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb., Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma Co. Ltd., Taisho Toyama Co. Ltd., and Towa Pharma Co. Ltd., and speaker fees from Bristol-Myers Squibb., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., and Mitsubishi Tanabe Pharma Corp. Ltd. YM has received honoraria from Asahi Kasei Pharma Corp. RW has received a grant from AbbVie GK, and has received honoraria from AbbVie GK, Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Corp., GlaxoSmithKline, Eli Lilly Japan K.K., and UCB Japan. KM has received honoraria from Chugai Pharmaceutical Co., Ltd., and Asahi Kasei Pharma Corp. AM has received research grants from AbbVie GK, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp. Ltd., and Eisai Co. Ltd., and has received honoraria from AbbVie GK, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Corp., Astellas Pharma Inc., and Gilead Sciences Japan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}